Amyotrophic Lateral Sclerosis Market
Amyotrophic Lateral Sclerosis (ALS) Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019–2030, Segmented By Type (Sporadic ALS (SALS), Familial ALS (FALS)); By Treatment (Medication, Physical Therapy, Respiratory Therapy, Speech Therapy); By End User (Specialty Centers, Research & Academic Institutes); By Region (North America, Europe, Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa (MEA))
- Published Date: August 2024
- Report ID: BWC24582
- Available Format: PDF
- Page: 400
Report Overview
Escalating ALS incidence, breakthroughs in therapeutics, enhanced research funding, and government support fostering early detection and improved patient management are expected to boost the growth of Global Amyotrophic Lateral Sclerosis (ALS) Market during the forecast period between 2024 and 2030.
Global Amyotrophic Lateral Sclerosis (ALS) Market – Industry Trends & Forecast Report, 2030
Global Amyotrophic Lateral Sclerosis (ALS) Market size was estimated at USD 902 million in 2023. During the forecast period between 2024 and 2030, Global Amyotrophic Lateral Sclerosis (ALS) Market size is expected to expand at a CAGR of 7.10% reaching a value of USD 1,456 million by 2030. Amyotrophic Lateral Sclerosis (ALS) Market across the regions is experiencing growth due to the increasing geriatric population, awareness of the disease, and its increasing incidence rate. The growth is expected to continue due to additional approvals for existing treatment options and the emergence of new drug therapies. ALS is a progressive neurodegenerative disorder that affects voluntary muscles, leading to muscle twitching, stiffness, and weakness. The disease is hereditary, with a 50% chance of inheriting a genetic mutation. Treatments like medications and stem cell therapies can help manage symptoms, prevent complications, and slow disease progression.
Amyotrophic Lateral Sclerosis (ALS) – Overview
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder affecting nerve cells in the brain and spinal cord, leading to muscle weakness, atrophy, and paralysis. Commonly known as Lou Gehrig's disease, it typically manifests with symptoms like difficulty in speaking, swallowing, and breathing. The exact cause is unknown, and there is no cure, though treatments like Riluzole and supportive therapies can slow progression and improve quality of life. ALS predominantly affects adults aged between 40 and 70 years.
Global Amyotrophic Lateral Sclerosis (ALS) Market
Growth Drivers
Increasing Incidence of Cancer
Global Amyotrophic Lateral Sclerosis Market is driven by the increasing prevalence of cancer, with patients dying from respiratory failure within 3-5 years. The sporadic type accounts for 90-95% of cases in the United States, while the familial type accounts for the rest. The increasing geriatric population and inclination towards a sedentary lifestyle are also driving demand for targeted treatment options, further driving the market growth.
Challenges
High Cost of ALS Treatment Options
The financial burden of treating Amyotrophic Lateral Sclerosis (ALS) is significant, as it requires extensive medical care, including medications, physical therapy, and assistive devices. The cost can be overwhelming, reaching tens of thousands of dollars annually. Home modifications and round-the-clock care further exacerbate the situation. Insurance coverage often falls short, limiting access to necessary treatments and services. Developing affordable treatment options and expanding insurance coverage are crucial for ALS patients.
Impact of Escalating Geopolitical Tensions on Global Amyotrophic Lateral Sclerosis (ALS) Market
Escalating geopolitical tensions can significantly impact Amyotrophic Lateral Sclerosis (ALS) research and patient care. Governments may prioritize defense spending, causing delays in ALS research. International collaborations may be strained, and trade restrictions could disrupt the supply chain. Patients in conflict zones may face limited access to healthcare facilities and specialized care. The psychological stress associated with geopolitical instability can worsen ALS symptoms.
Global Amyotrophic Lateral Sclerosis (ALS) Market
Segmental Information
Global Amyotrophic Lateral Sclerosis (ALS) Market – By Type
By type, Global Amyotrophic Lateral Sclerosis (ALS) Market is split into Sporadic ALS (SALS) and Familial ALS (FALS) segments. The sporadic ALS (SALS) segment hodls a higher market share in Global Amyotrophic Lateral Sclerosis (ALS) Market. SALS accounts for the majority of ALS cases, representing approximately 90–95% of the total. It occurs randomly without a clear familial link or genetic cause, making it more prevalent than Familial ALS (FALS), which is hereditary and represents about 5–10% of cases. The high incidence of SALS drives its dominance in the ALS market.
Global Amyotrophic Lateral Sclerosis (ALS) Market – By Treatment
By treatment, Global Amyotrophic Lateral Sclerosis (ALS) Market is divided into Medication, Physical Therapy, Respiratory Therapy, and Speech Therapy segments. Medication is the largest treatment segment in Global Amyotrophic Lateral Sclerosis (ALS) Market. The segment’s dominance is attributed to the significant reliance on pharmaceutical interventions to manage symptoms and slow disease progression. Medications such as Riluzole and Edaravone are widely prescribed, and ongoing research into new drugs continues to drive growth in this segment. The high cost of these medications also contributes to the larger market share compared to other therapeutic approaches like physical, respiratory, and speech therapies.
Global Amyotrophic Lateral Sclerosis (ALS) Market – By Region
Regionally, Global Amyotrophic Lateral Sclerosis (ALS) Market is divided into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), and Middle East and Africa (MEA). North America holds a major share of Global Amyotrophic Lateral Sclerosis (ALS) Market. The dominance is attributed to the region's advanced healthcare infrastructure, high awareness about ALS, significant investment in research and development, and the presence of key market players. The United States, in particular, plays a pivotal role due to its robust support for ALS research and extensive patient care programs.
Competitive Landscape
Key players in the highly competitive Global Amyotrophic Lateral Sclerosis (ALS) Market include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd, BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
Scope of the Report
Attributes |
Details |
Years Considered |
Historical Data – 2019–2023 |
Base Year – 2023 |
|
Estimated Year – 2024 |
|
Forecast Period – 2024–2030 |
|
Facts Covered |
Revenue in USD Million |
Market Coverage |
North America, Europe, Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa (MEA) |
Product/Service Segmentation |
Type, Treatment, End User, Region |
Key Players |
Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd, BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, Ionis Pharmaceuticals, Inc. |
By Type
-
Sporadic ALS (SALS)
-
Familial ALS (FALS)
By Treatment
-
Medication
-
Physical Therapy
-
Respiratory Therapy
-
Speech Therapy
-
Others
By End User
-
Specialty Centers
-
Research & Academic Institutes
-
Others
By Region
-
North America
-
Europe
-
Asia Pacific (APAC)
-
Latin America (LATAM)
-
Middle East and Africa (MEA)
- Research Framework
- Research Objective
- Product Overview
- Market Segmentation
- Executive Summary
- Global Amyotrophic Lateral Sclerosis (ALS) Market Insights
- Industry Value Chain Analysis
- DROC Analysis
- Growth Drivers
- Increasing prevalence of ALS globally
- Advances in medical research and technology for ALS treatment
- Growing healthcare expenditure and awareness
- Rising geriatric population susceptible to neurological disorders
- Restraints
- High cost of ALS treatment options
- Limited effectiveness of current therapies
- Stringent regulatory requirements for drug approval
- Opportunities
- Research and development initiatives for novel therapies
- Collaborations between pharmaceutical companies and research institutions
- Technological advancements in diagnostic tools for early detection
- Challenges
- Ethical concerns related to experimental ALS therapies
- Uneven access to ALS treatments across different regions
- Growth Drivers
- Technological Advancements/Recent Developments
- Regulatory Framework
- Porter’s Five Forces Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of New Entrants
- Threat of Substitutes
- Intensity of Rivalry
- Global Amyotrophic Lateral Sclerosis (ALS) Market: Marketing Strategies
- Global Amyotrophic Lateral Sclerosis (ALS) Market: Pricing Analysis
- Global Amyotrophic Lateral Sclerosis (ALS) Market: Geographical Analysis
- Global Amyotrophic Lateral Sclerosis (ALS) Market Overview
- Market Size & Forecast, 2019–2030
- By Value (USD Billion)
- Market Share and Forecast
- By Type
- Sporadic ALS (SALS)
- Familial ALS (FALS)
- By Treatment
- Medication
- Physical Therapy
- Respiratory Therapy
- Speech Therapy
- Others
- By End User
- Specialty Centers
- Research & Academic Institutes
- Others
- By Region
- North America
- Europe
- Asia Pacific (APAC)
- Latin America (LATAM)
- Middle East and Africa (MEA)
- By Type
- Market Size & Forecast, 2019–2030
- North America Amyotrophic Lateral Sclerosis (ALS) Market
- Market Size & Forecast, 2019–2030
- By Value (USD Billion)
- Market Share & Forecast
- By Type
- By Treatment
- By End User
- By Country
- United States
- By Type
- By Treatment
- By End User
- Canada
- By Type
- By Treatment
- By End User
- United States
- Market Size & Forecast, 2019–2030
- Europe Amyotrophic Lateral Sclerosis (ALS) Market
- Market Size & Forecast, 2019–2030
- By Value (USD Billion)
- Market Share & Forecast
- By Type
- By Treatment
- By End User
- By Country
- Germany
- By Type
- By Treatment
- By End User
- United Kingdom
- By Type
- By Treatment
- By End User
- Italy
- By Type
- By Treatment
- By End User
- France
- By Type
- By Treatment
- By End User
- Spain
- By Type
- By Treatment
- By End User
- Belgium
- By Type
- By Treatment
- By End User
- Russia
- By Type
- By Treatment
- By End User
- The Netherlands
- By Type
- By Treatment
- By End User
- Rest of Europe
- By Type
- By Treatment
- By End User
- Germany
- Market Size & Forecast, 2019–2030
- Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market
- Market Size & Forecast, 2019–2030
- By Value (USD Billion)
- Market Share & Forecast
- By Type
- By Treatment
- By End User
- By Country
- China
- By Type
- By Treatment
- By End User
- India
- By Type
- By Treatment
- By End User
- Japan
- By Type
- By Treatment
- By End User
- South Korea
- By Type
- By Treatment
- By End User
- Australia & New Zealand
- By Type
- By Treatment
- By End User
- Indonesia
- By Type
- By Treatment
- By End User
- Malaysia
- By Type
- By Treatment
- By End User
- Singapore
- By Type
- By Treatment
- By End User
- Vietnam
- By Type
- By Treatment
- By End User
- Rest of APAC
- By Type
- By Treatment
- By End User
- China
- Market Size & Forecast, 2019–2030
- Latin America Amyotrophic Lateral Sclerosis (ALS) Market
- Market Size & Forecast, 2019–2030
- By Value (USD Billion)
- Market Share & Forecast
- By Type
- By Treatment
- By End User
- By Country
- Brazil
- By Type
- By Treatment
- By End User
- Mexico
- By Type
- By Treatment
- By End User
- Argentina
- By Type
- By Treatment
- By End User
- Peru
- By Type
- By Treatment
- By End User
- Rest of LATAM
- By Type
- By Treatment
- By End User
- Brazil
- Market Size & Forecast, 2019–2030
- Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Market
- Market Size & Forecast, 2019–2030
- By Value (USD Billion)
- Market Share & Forecast
- By Type
- By Treatment
- By End User
- By Country
- Saudi Arabia
- By Type
- By Treatment
- By End User
- UAE
- By Type
- By Treatment
- By End User
- Qatar
- By Type
- By Treatment
- By End User
- Kuwait
- By Type
- By Treatment
- By End User
- South Africa
- By Type
- By Treatment
- By End User
- Nigeria
- By Type
- By Treatment
- By End User
- Algeria
- By Type
- By Treatment
- By End User
- Rest of MEA
- By Type
- By Treatment
- By End User
- Saudi Arabia
- Market Size & Forecast, 2019–2030
- Competitive Landscape
- List of Key Players and Their Offerings
- Global Amyotrophic Lateral Sclerosis (ALS) Market Share Analysis, 2023
- Competitive Benchmarking, By Operating Parameters
- Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
- Impact of Escalating Geopolitical Tensions on Global Amyotrophic Lateral Sclerosis (ALS) Market
- Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
- Mitsubishi Tanabe Pharma Corporation
- Otsuka Pharmaceutical Co., Ltd
- BrainStorm Therapeutics
- Biogen Inc.
- Corestem
- AB Science
- F.Hoffmann-La Roche AG
- Biohaven Pharmaceutical
- Sun Pharmaceutical
- Ionis Pharmaceuticals, Inc.
- Other Prominent Players
- Key Strategic Recommendations
- Research Methodology
- Qualitative Research
- Primary & Secondary Research
- Quantitative Research
- Market Breakdown & Data Triangulation
- Secondary Research
- Primary Research
- Breakdown of Primary Research Respondents, By Region
- Assumptions & Limitations
- Qualitative Research
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable
List of Figures
Figure 1 Global Amyotrophic Lateral Sclerosis (ALS) Segmentation
Figure 2 Global Amyotrophic Lateral Sclerosis (ALS) Market Value Chain Analysis
Figure 3 Company Market Share Analysis, 2023
Figure 4 Global Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 5 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 6 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 7 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 8 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Region, By Value, 2019–2030
Figure 9 North America Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 10 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 11 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 12 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 13 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030
Figure 14 United States Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 15 United States Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 16 United States Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 17 United States Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 18 Canada Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 19 Canada Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 20 Canada Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 21 Canada Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 22 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 23 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 24 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 25 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 26 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030
Figure 27 Germany Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 28 Germany Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 29 Germany Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 30 Germany Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 31 United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 32 United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 33 United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 34 United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 35 Italy Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 36 Italy Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 37 Italy Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 38 Italy Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 39 France Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 40 France Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 41 France Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 42 France Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 43 Spain Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 44 Spain Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 45 Spain Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 46 Spain Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 47 Belgium Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 48 Belgium Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 49 Belgium Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 50 Belgium Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 51 Russia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 52 Russia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 53 Russia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 54 Russia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 55 The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 56 The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 57 The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 58 The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 59 Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 60 Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 61 Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 62 Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 63 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 64 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 65 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 66 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 67 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030
Figure 68 China Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 69 China Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 70 China Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 71 China Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 72 India Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 73 India Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 74 India Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 75 India Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 76 Japan Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 77 Japan Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 78 Japan Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 79 Japan Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 80 South Korea Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 81 South Korea Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 82 South Korea Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 83 South Korea Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 84 Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 85 Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 86 Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 87 Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 88 Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 89 Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 90 Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 91 Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 92 Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 93 Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 94 Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 95 Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 96 Singapore Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 97 Singapore Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 98 Singapore Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 99 Singapore Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 100 Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 101 Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 102 Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 103 Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 104 Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 105 Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 106 Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 107 Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 108 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 109 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 110 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 111 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 112 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030
Figure 113 Brazil Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 114 Brazil Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 115 Brazil Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 116 Brazil Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 117 Mexico Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 118 Mexico Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 119 Mexico Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 120 Mexico Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 121 Argentina Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 122 Argentina Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 123 Argentina Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 124 Argentina Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 125 Peru Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 126 Peru Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 127 Peru Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 128 Peru Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 129 Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 130 Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 131 Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 132 Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 133 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 134 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 135 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 136 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 137 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030
Figure 138 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 139 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 140 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 141 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 142 UAE Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 143 UAE Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 144 UAE Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 145 UAE Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 146 Qatar Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 147 Qatar Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 148 Qatar Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 149 Qatar Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 150 Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 151 Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 152 Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 153 Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 154 South Africa Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 155 South Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 156 South Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 157 South Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 158 Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 159 Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 160 Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 161 Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 162 Algeria Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 163 Algeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 164 Algeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 165 Algeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Figure 166 Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Figure 167 Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Figure 168 Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Figure 169 Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
List of Tables
Table 1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 2 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 3 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 4 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 5 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Region, By Value, 2019–2030
Table 6 North America Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 7 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 8 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 9 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 10 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030
Table 11 United States Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 12 United States Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 13 United States Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 14 United States Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 15 Canada Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 16 Canada Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 17 Canada Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 18 Canada Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 19 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 20 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 21 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 22 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 23 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030
Table 24 Germany Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 25 Germany Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 26 Germany Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 27 Germany Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 28 United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 29 United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 30 United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 31 United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 32 Italy Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 33 Italy Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 34 Italy Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 35 Italy Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 36 France Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 37 France Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 38 France Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 39 France Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 40 Spain Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 41 Spain Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 42 Spain Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 43 Spain Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 44 Belgium Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 45 Belgium Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 46 Belgium Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 47 Belgium Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 48 Russia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 49 Russia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 50 Russia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 51 Russia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 52 The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 53 The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 54 The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 55 The Netherlands Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 56 Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 57 Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 58 Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 59 Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 60 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 61 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 62 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 63 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 64 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030
Table 65 China Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 66 China Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 67 China Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 68 China Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 69 India Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 70 India Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 71 India Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 72 India Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 73 Japan Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 74 Japan Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 75 Japan Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 76 Japan Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 77 South Korea Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 78 South Korea Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 79 South Korea Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 80 South Korea Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 81 Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 82 Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 83 Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 84 Australia & New Zealand Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 85 Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 86 Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 87 Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 88 Indonesia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 89 Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 90 Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 91 Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 92 Malaysia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 93 Singapore Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 94 Singapore Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 95 Singapore Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 96 Singapore Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 97 Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 98 Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 99 Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 100 Vietnam Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 101 Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 102 Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 103 Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 104 Rest of APAC Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 105 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 106 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 107 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 108 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 109 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030
Table 110 Brazil Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 111 Brazil Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 112 Brazil Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 113 Brazil Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 114 Mexico Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 115 Mexico Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 116 Mexico Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 117 Mexico Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 118 Argentina Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 119 Argentina Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 120 Argentina Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 121 Argentina Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 122 Peru Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 123 Peru Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 124 Peru Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 125 Peru Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 126 Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 127 Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 128 Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 129 Rest of LATAM Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 130 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 131 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 132 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 133 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 134 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, By Value, 2019–2030
Table 135 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 136 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 137 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 138 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 139 UAE Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 140 UAE Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 141 UAE Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 142 UAE Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 143 Qatar Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 144 Qatar Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 145 Qatar Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 146 Qatar Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 147 Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 148 Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 149 Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 150 Kuwait Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 151 South Africa Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 152 South Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 153 South Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 154 South Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 155 Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 156 Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 157 Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 158 Nigeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 159 Algeria Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 160 Algeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 161 Algeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 162 Algeria Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 163 Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Size, By Value (USD Billion), 2019–2030
Table 164 Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Share, By Type, By Value, 2019–2030
Table 165 Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment, By Value, 2019–2030
Table 166 Rest of MEA Amyotrophic Lateral Sclerosis (ALS) Market Share, By End User, By Value, 2019–2030
Table 167 Mitsubishi Tanabe Pharma Corporation Company Overview
Table 168 Mitsubishi Tanabe Pharma Corporation Financial Overview
Table 169 Otsuka Pharmaceutical Co., Ltd Company Overview
Table 170 Otsuka Pharmaceutical Co., Ltd Financial Overview
Table 171 BrainStorm Therapeutics Company Overview
Table 172 BrainStorm Therapeutics Financial Overview
Table 173 Biogen Inc. Company Overview
Table 174 Biogen Inc. Financial Overview
Table 175 Corestem Company Overview
Table 176 Corestem Financial Overview
Table 177 AB Science Company Overview
Table 178 AB Science Financial Overview
Table 179 F.Hoffmann-La Roche AG Company Overview
Table 180 F.Hoffmann-La Roche AG Financial Overview
Table 181 Biohaven Pharmaceutical Company Overview
Table 182 Biohaven Pharmaceutical Financial Overview
Table 183 Sun Pharmaceutical Company Overview
Table 184 Sun Pharmaceutical Financial Overview
Table 185 Ionis Pharmaceuticals, Inc. Company Overview
Table 186 Ionis Pharmaceuticals, Inc. Financial Overview
Market Segmentation
To request a free sample copy of this report, please complete the form below.
We value your investment and offer free customization with every report to fulfil your exact research needs.
Frequently Asked Questions (FAQs):
RELATED REPORTS
WHY CHOOSE US
-
24/7 Research Support
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
-
Custom Research Service
Ask the Analyst to customize an exclusive study to serve your research needs
-
Quality & Accuracy
Ask the Analyst to customize an exclusive study to serve your research needs
-
Data Visualization
As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization
-
Information security
We never share your personal and confidential information. Your personal information is safe and secure with us.